Immunotherapy drugs are now eliminating certain cancers without surgery, chemotherapy, or radiation, offering patients a dramatically different treatment experience than just a decade ago. A groundbreaking approach identifies patients whose tumors carry a specific genetic signature, allowing doctors to predict which individuals will respond best to immune checkpoint inhibitor drugs. In recent trials, this personalized strategy has produced remarkable results: 84 of 103 patients with various solid tumors saw complete disappearance of their cancer after treatment .

When 71-year-old Maureen Sideris was diagnosed with oesophageal cancer approximately 14 years after her 2008 colon cancer surgery, her treatment looked nothing like her earlier experience. Instead of going under the knife, she received infusions of dostarlimab, an immune checkpoint inhibitor, every three weeks at Memorial Sloan Kettering Cancer Center in New York City. After just four months, her tumor had vanished completely. "It's unbelievable," Sideris said. "It's almost like science fiction" .

What Makes Immunotherapy Different From Traditional Cancer Treatments?

Immunotherapy works by fundamentally changing how the body fights cancer. Instead of attacking tumors directly with surgery, chemotherapy, or radiation, these drugs boost the immune system's natural ability to recognize and destroy cancer cells. The body's immune system has built-in "off switches" designed to prevent it from attacking healthy tissue. Cancer cells exploit this safeguard by flipping that switch, essentially hiding from immune detection. Immune checkpoint inhibitors disable that off switch, allowing T cells (specialized immune cells) to identify cancer cells as threats and launch an attack .

"People are living, and living with good quality lives. We're talking about cures," said Jennifer Wargo.

Jennifer Wargo, Professor of Surgical Oncology, MD Anderson Cancer Center

This approach offers significant advantages over traditional treatments. Patients experience fewer side effects, better quality of life during treatment, and the potential for long-term remission. However, immunotherapy isn't a one-size-fits-all solution. Historically, only between 20% and 40% of patients respond to these drugs, meaning the majority open themselves to side effects without much benefit .

How Are Doctors Now Predicting Which Patients Will Benefit?

The key breakthrough involves genetic profiling. Scientists at Memorial Sloan Kettering discovered that tumors with a particular genetic signature respond exceptionally well to immune checkpoint inhibitors like dostarlimab. This finding has transformed treatment planning from a guessing game into a precision strategy. Researchers identified this genetic profile in patients with rectal, oesophageal, bladder, and stomach cancers, then tested the approach in two small trials in 2022 and 2024 treating rectal cancers. The results were striking: tumors completely eradicated in all patients tested .

The team then expanded their research to include 117 patients with various tumor types carrying the same genetic signature. Of the 103 people who completed the full treatment course, 84 saw complete tumor disappearance. Only two patients required additional surgery afterward . Researchers from MD Anderson have reported similar success using a different checkpoint inhibitor, suggesting this personalized approach works across multiple drug types .

Ways to Optimize Immunotherapy Response

Beyond genetic matching, researchers are discovering that several lifestyle and treatment factors can enhance how well immunotherapy works. These findings suggest that maximizing treatment success involves more than just the drug itself.

• Dietary Choices: Preliminary research suggests that patients following high-fiber diets may see better immunotherapy results through changes to the gut microbiome that affect both immune function and tumor visibility .
• Cholesterol Medications: Surprising research indicates that statins, inexpensive cholesterol-lowering drugs already used by millions, may enhance immunotherapy effects through unexpected changes to cell communication .
• Treatment Timing: Recent research hints that patients dosed with immunotherapy early in the day may fare better than those treated later, suggesting circadian rhythms may influence drug effectiveness .

Researchers are also exploring combination approaches. Radiation therapy can make tumors more visible to the immune system, potentially boosting response rates when combined with immunotherapy. Ultrasound therapy, which uses high-frequency sound waves to attack tumors, may work similarly .

The shift toward personalized medicine represents a fundamental change in how oncologists approach cancer treatment. "The field is at an inflection point," explained Sandra Demaria. "We can now move toward treating not the cancer, but actually the patient" .

"Cancer is not one disease. It's 200 different diseases, and they all arise due to different reasons and they have to be treated differently," noted Karen Knudsen.

Karen Knudsen, Chief Executive, Parker Institute for Cancer Immunotherapy

This personalized approach acknowledges that two patients with identical cancer diagnoses may have fundamentally different diseases at the cellular level, requiring different treatment strategies. By matching patients to therapies based on their tumor's genetic profile, doctors are moving away from trial-and-error treatment toward precision oncology .

While immunotherapy side effects remain a consideration, they differ markedly from traditional chemotherapy. Common side effects include skin rashes, diarrhea, and fatigue. In rare cases, the immune system can become overactive and inflame the liver, heart, or kidneys. For Sideris, the main side effect was adrenal insufficiency causing fatigue, a manageable trade-off for complete tumor elimination without surgery .

The success of these personalized immunotherapy approaches is reshaping cancer care. As more patients benefit from treatments tailored to their tumor's genetic makeup, the promise of immunotherapy is finally being realized for solid tumors, which account for more than 90% of new cancer diagnoses. For patients like Sideris, the results speak for themselves: a cancer-free life without the grueling recovery of traditional surgery.